Pioglitazone

From Ganfyd

Revision as of 23:07, 10 June 2011 by Mlj (Talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search

Contents

Introduction

Clinical Use

The nature of the licensing process based of surrogate outcomes means that there are still information gaps that mean the clinical risk benefit ratio is not fully understood. This also applies to any other medication that has entered the diabetic market in the last 10 years. By the middle of 2011 sufficient evidence of an association with bladder cancer had arisen[1] that national regulators started withdrawing marketing authorization[2].

Indications

Possible indications

Administration

Oral

Clinical Issues

Contra-indications

  • Renal failure
  • Heart failure

Cautions and Interactions

Side effects

Class side effects

Possible Association

  • Bladder cancer in long term use[1]

Special advice

Pharmacology

References

Personal tools